| 15.10 15:45 | MÄRKTE USA/Börsen bleiben in Schlagweite zu jüngsten Hochs |
| 15.10 14:55 | MÄRKTE USA/Börsen in Schlagweite zu jüngsten Allzeithochs |
| 15.10 14:21 | dpa-AFX: *J&J : NIPOCALIMAB PHASE 2/3 STUDY SHOWS SUSTAINED DISEASE CONTROL IN ADOLESCENTS WITH GENERALIZED MYASTHENIA GRAVIS |
| 15.10 14:10 | dpa-AFX: Übernahme von V-Wave dürfte Gewinn von Johnson & Johnson schmälern |
| 15.10 14:10 | Übernahme von V-Wave dürfte Gewinn von Johnson & Johnson schmälern |
| 15.10 14:05 | dpa-AFX: Übernahme von V-Wave dürfte Gewinn von Johnson & Johnson schmälern |
| 15.10 13:11 | dpa-AFX: ROUNDUP: Johnson & Johnson Cuts FY24 Earnings View, Lifts Sales Forecast |
| 15.10 12:29 | dpa-AFX: *JOHNSON & JOHNSON (JNJ) DECLARES $ 1.24 DIVIDEND FOR Q4 24, RECORD DATE 11/26/2024 |
| 15.10 12:28 | dpa-AFX: *JOHNSON & JOHNSON VORBÖRSLICH +1,8% - QUARTALSGEWINN HÖHER ALS ERWARTET |
| 15.10 12:28 | dpa-AFX: *JOHNSON & JOHNSON NOW SEES FY ADJUSTED EPS/ MID-POINT OF $9.88 - $9.98 / $9.93 |
| 15.10 12:28 | dpa-AFX: *JOHNSON & JOHNSON NOW SEES FY ADJUSTED OPERATIONAL EPS/ MID-POINT OF $9.86 - $9.96 / $9.91 |
| 15.10 12:27 | dpa-AFX: Johnson & Johnson Q3 Profit Decreases, But Beats Estimates |
| 15.10 12:23 | dpa-AFX: *JOHNSON & JOHNSON Q3 REPORTED SALES $22.471 BLN VS $21.351 BLN LAST YEAR |
| 15.10 12:23 | dpa-AFX: *JOHNSON & JOHNSON Q3 NET EARNINGS $2.694 BLN; ADJ NET EARNINGS $5.876 BLN |
| 15.10 12:21 | dpa-AFX: *JOHNSON & JOHNSON Q3 EPS $1.11; ADJ EPS $2.42 |
| 15.10 12:03 | dpa-AFX: Johnson & Johnson Q3 24 Earnings Conference Call At 8:30 AM ET |
| 10.10 15:12 | dpa-AFX: J&J Says TREMFYA Showed Strong Results In Biologic-Naive & Refractory Patients With CD And UC |
| 10.10 14:06 | dpa-AFX: *J&J :TREMFYA SHOWS STRONG RESULTS IN BIOLOGIC-NAIVE & REFRACTORY PATIENTS WITH CROHN'S AND ULCERATIVE COLITIS |
| 10.10 13:58 | dpa-AFX: J&J Submits For EMA Approval For DARZALEX SC Quadruplet Regimen In Newly Diagnosed Multiple Myeloma |
| 10.10 13:40 | dpa-AFX: *J&J SEEKS EMA APPROVAL FOR DARZALEX SC QUADRUPLET REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA |
|
|
